Ratings Humana Inc.

Equities

HUM

US4448591028

Real-time Estimate Cboe BZX Other stock markets 08:03:19 29/04/2024 pm IST			5-day change	1st Jan Change
304.6 ^USD	-0.44%		-6.09%	-33.27%

26/04	Deutsche Bank Adjusts Price Target on Humana to $341 From $355	MT
26/04	HCA beats first-quarter profit estimates on higher patient admissions	RE

Summary

The company's Refinitiv ESG score, based on a ranking of the company relative to its industry, comes out particularly well.

Strengths

The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.37 for the 2024 fiscal year.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.

Weaknesses

With relatively low growth outlooks, the group is not among those with the highest revenue growth potential.
The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
The company has insufficient levels of profitability.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Over the past four months, analysts' average price target has been revised downwards significantly.
The overall consensus opinion of analysts has deteriorated sharply over the past four months.
Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings chart - Surperformance

Chart ESG Refinitiv

Sector: Managed Healthcare

	1st Jan change	Capi.	ESG Refinitiv
HUMANA INC.	-33.27%	36.86B	A-
UNITEDHEALTH GROUP INC.	-6.50%	456B	B-
ELEVANCE HEALTH, INC.	+13.90%	125B	A-
CIGNA	+19.38%	101B	B-
CENTENE CORPORATION	-0.37%	39.69B	B-
MOLINA HEALTHCARE, INC.	-5.06%	20.05B	B-
PROGYNY, INC.	-12.94%	3.08B	C+
ALIGNMENT HEALTHCARE, INC.	-37.80%	993M	B-
CLOVER HEALTH INVESTMENTS, CORP.	-29.13%	337M	-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Environment

Emissions

Innovation

Use of resources

Governance

CSR Strategy

Management

Shareholders

Controversy

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes